Testim Gel Suppresses Th2 Allergy Pathways, Asthma in Hypogonadal Men
Reading Time: < 1 minute Introduction Testosterone replacement therapy (TRT), particularly transdermal formulations like Testim 1% testosterone gel, has revolutionized hypogonadism management in American males. With over 2.5 million U.S. men aged 40-70 receiving TRT annually (per CDC data), emerging evidence suggests immunomodulatory effects beyond androgen restoration. Allergic reactions and asthma, prevalent in 10-15% of adult males, involve Th2-skewed immune responses characterized by elevated IgE, eosinophilia, and IL-4/IL-13 cytokine cascades. This study investigates Testim's impact on these pathways, hypothesizing testosterone's suppression of mast cell degranulation and bronchial hyperreactivity via androgen receptor (AR) signaling in immune cells. Study Design and Methodology A prospective, open-label cohort study...


